Literature DB >> 29897428

Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.

Hector M Garcia-Garcia1,2, Eugène P McFadden3, Andrew Farb4, Roxana Mehran5, Gregg W Stone6, John Spertus7, Yoshinobu Onuma1, Marie-Angèle Morel1, Gerrit-Anne van Es1, Bram Zuckerman4, William F Fearon8, David Taggart9, Arie-Pieter Kappetein10, Mitchell W Krucoff11, Pascal Vranckx12, Stephan Windecker13, Donald Cutlip14, Patrick W Serruys15.   

Abstract

The Academic Research Consortium (ARC)-2 initiative revisited the clinical and angiographic end point definitions in coronary device trials, proposed in 2007, to make them more suitable for use in clinical trials that include increasingly complex lesion and patient populations and incorporate novel devices such as bioresorbable vascular scaffolds. In addition, recommendations for the incorporation of patient-related outcomes in clinical trials are proposed. Academic Research Consortium-2 is a collaborative effort between academic research organizations in the United States and Europe, device manufacturers, and European, US, and Asian regulatory bodies. Several in-person meetings were held to discuss the changes that have occurred in the device landscape and in clinical trials and regulatory pathways in the last decade. The consensus-based end point definitions in this document are endorsed by the stakeholders of this document and strongly advocated for clinical trial purposes. This Academic Research Consortium-2 document provides further standardization of end point definitions for coronary device trials, incorporating advances in technology and knowledge. Their use will aid interpretation of trial outcomes and comparison among studies, thus facilitating the evaluation of the safety and effectiveness of these devices.

Entities:  

Mesh:

Year:  2018        PMID: 29897428     DOI: 10.1093/eurheartj/ehy223

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  29 in total

1.  The year in cardiology 2018: coronary interventions.

Authors:  Dariusz Dudek; Artur Dziewierz; Gregg Stone; William Wijns
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983

2.  The Prognostic Value of Cardiac Troponin I in Patients with or without Three-Vessel Disease Undergoing Complete Percutaneous Coronary Intervention.

Authors:  Zhi-Fan Li; Shuang Zhang; Hui-Wei Shi; Wen-Jia Zhang; Yong-Gang Sui; Jian-Jun Li; Ke-Fei Dou; Jie Qian; Na-Qiong Wu
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

3.  Safety of conservative management for non-stenotic culprit lesions in STEMI patients treated with a two-step reperfusion strategy: a SUPER-MIMI sub-study.

Authors:  Marc Bonnet; Stephanie Marliere; Victor Mathieu; Allan Tronchi; Nicolas Delarche; Mohamed Abdellaoui; Olivier Dubreuil; Ziad Boueri; Mohamed Chettibi; Geraud Souteyrand; Chloé Durier; Frederic Bouisset; Loic Belle
Journal:  Cardiovasc Diagn Ther       Date:  2022-04

4.  Validity of the Stent Thrombosis Risk Score in Predicting Early Stent Thrombosis after Primary Percutaneous Coronary Intervention.

Authors:  Rajesh Kumar; Sahar Tariq; Madiha Fatima; Tahir Saghir; Mahesh Kumar Batra; Musa Karim; Jawaid Akbar Sial; Naveedullah Khan; Syed Nadeem Hasan Rizvi
Journal:  J Saudi Heart Assoc       Date:  2020-06-01

5.  Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy.

Authors:  Nader Mankerious; Rayyan Hemetsberger; Hussein Traboulsi; Ralph Toelg; Mohamed Abdel-Wahab; Gert Richardt; Abdelhakim Allali
Journal:  Clin Res Cardiol       Date:  2021-04-16       Impact factor: 5.460

6.  Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.

Authors:  Bernard R Chaitman; Karen P Alexander; Derek D Cyr; Jeffrey S Berger; Harmony R Reynolds; Sripal Bangalore; William E Boden; Renato D Lopes; Marcin Demkow; Gian Piero Perna; Robert K Riezebos; Edward O McFalls; Subhash Banerjee; Akshay Bagai; Gilbert Gosselin; Sean M O'Brien; Frank W Rockhold; David D Waters; Kristian A Thygesen; Gregg W Stone; Harvey D White; David J Maron; Judith S Hochman
Journal:  Circulation       Date:  2020-12-03       Impact factor: 29.690

7.  Impact of diabetes on coronary physiology evaluated by quantitative flow ratio in patients who underwent percutaneous coronary intervention.

Authors:  Zhen Ye; Qin Chen; Jiaxin Zhong; Long Chen; Lihua Chen; Mingfang Ye; Yuanming Yan; Lianglong Chen; Yukun Luo
Journal:  J Diabetes Investig       Date:  2022-03-29       Impact factor: 3.681

8.  Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Heerajnarain Bulluck; Valeria Paradies; Emanuele Barbato; Andreas Baumbach; Hans Erik Bøtker; Davide Capodanno; Raffaele De Caterina; Claudio Cavallini; Sean M Davidson; Dmitriy N Feldman; Péter Ferdinandy; Sebastiano Gili; Mariann Gyöngyösi; Vijay Kunadian; Sze-Yuan Ooi; Rosalinda Madonna; Michael Marber; Roxana Mehran; Gjin Ndrepepa; Cinzia Perrino; Stefanie Schüpke; Johanne Silvain; Joost P G Sluijter; Giuseppe Tarantini; Gabor G Toth; Linda W Van Laake; Clemens von Birgelen; Michel Zeitouni; Allan S Jaffe; Kristian Thygesen; Derek J Hausenloy
Journal:  Eur Heart J       Date:  2021-07-15       Impact factor: 29.983

9.  Prognostic Implications of Resistive Reserve Ratio in Patients With Coronary Artery Disease.

Authors:  Seung Hun Lee; Joo Myung Lee; Jonghanne Park; Ki Hong Choi; Doyeon Hwang; Joon-Hyung Doh; Chang-Wook Nam; Eun-Seok Shin; Masahiro Hoshino; Tadashi Murai; Taishi Yonetsu; Hernán Mejía-Rentería; Tsunekazu Kakuta; Javier Escaned
Journal:  J Am Heart Assoc       Date:  2020-04-18       Impact factor: 5.501

10.  First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry.

Authors:  Ian B A Menown; Mamas A Mamas; James M Cotton; David Hildick-Smith; Franz R Eberli; Gregor Leibundgut; Damras Tresukosol; Carlos Macaya; Samuel Copt; Sara Sadozai Slama; Hans-Peter Stoll
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.